C4 Therapeutics shares are trading lower. The company announced the abstract sharing clinical data from its ongoing Phase 1 clinical trial of CFT1946 in mutant BRAF V600 solid tumors, was released in conjunction with the ESMO Congress 2024.
Portfolio Pulse from Benzinga Newsdesk
C4 Therapeutics shares are trading lower following the release of clinical data from its Phase 1 trial of CFT1946 for BRAF V600 mutant solid tumors, shared at the ESMO Congress 2024.
September 09, 2024 | 11:39 am
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
C4 Therapeutics' stock is experiencing a decline after the release of clinical data from its Phase 1 trial of CFT1946, targeting BRAF V600 mutant solid tumors, at the ESMO Congress 2024.
The release of clinical trial data often impacts biotech stocks significantly. In this case, the data from C4 Therapeutics' Phase 1 trial of CFT1946 was not well-received, leading to a decline in share price. The market's reaction suggests concerns about the trial's results or future prospects.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100